SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2012 / Cilt: 3 - Sayı: 3

Divalproex sodium and topiramate for migraine prophylaxis

Migren proflaksisinde topiramat ve divalproeks sodyum

Erkan Taner KARAGÖZ
Yıldız DEĞİRMENCİ
Handan Işın ÖZIŞIK KARAMAN
Pages
303–307
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Reduction from baseline migraine frequency at the end of six month was primary outcome measure.Mean migraine frequency at the end of study was 1.27 ± 1 (baseline; mean ± SD: 3.6 ± 2) in the first, 1.2 ± 1.2 (baseline; mean ± SD: 3.5 ± 2.3) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim:To compare the efficacy, safety of topiramate and extended-release divalproex sodium in migraine prophylaxis.
📊
Key Findings & Data:Material and Method: Study groups consisted of 22 patients with chronic migraine, randomly administered 1000 mg extended-release divalproex sodium (first group), 21 patients given 100 mg topiramate (second group).Study was 28-week randomized, prospective trial including 4-week baseline, 4-week titration, 20-week maintenance phase.Primary efficacy measure was reduction from baseline in 4-week migraine frequency.Secondary efficacy measures included responder rates, mean reduction in migraine duration,severity.Severity of headache was quantified by using 10-point visual analogue scale (VAS).
💡
Conclusion & Impact:Results: Reduction from baseline migraine frequency at the end of six month was primary outcome measure.Mean migraine frequency at the end of study was 1.27 ± 1 (baseline; mean ± SD: 3.6 ± 2) in the first, 1.2 ± 1.2 (baseline; mean ± SD: 3.5 ± 2.3) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim:To compare the efficacy, safety of topiramate and extended-release divalproex sodium in migraine prophylaxis. Material and Method: Study groups consisted of 22 patients with chronic migraine, randomly administered 1000 mg extended-release divalproex sodium (first group), 21 patients given 100 mg topiramate (second group).Study was 28-week randomized, prospective trial including 4-week baseline, 4-week titration, 20-week maintenance phase.Primary efficacy measure was reduction from baseline in 4-week migraine frequency.Secondary efficacy measures included responder rates, mean reduction in migraine duration,severity.Severity of headache was quantified by using 10-point visual analogue scale (VAS). Responder rates were defined as percentage of patients who demonstrated ≥ 50%. reduction in migraine frequency per month. Results: Reduction from baseline migraine frequency at the end of six month was primary outcome measure.Mean migraine frequency at the end of study was 1.27 ± 1 (baseline; mean ± SD: 3.6 ± 2) in the first, 1.2 ± 1.2 (baseline; mean ± SD: 3.5 ± 2.3) (p

Özet

Amaç:Migren proflaksisinde topiramat ve uzun salınımlı divalproeks sodyumun etkinliğini ve güvenilirliğini karşılaştırmak. Gereç ve Yöntem: Bu randomize, prospektif çalışmada gruplar, 1000 mg uzun salınımlı divalproeks sodyum uygulanan 22 (birinci grup) ve 100 mg topiramat verilen 21 (ikinci grup) kronik migren hastasından oluşmaktadır. Yirmi sekiz haftalık çalışma süresi, 4 haftalık bazal fazı, 4 haftalık titrasyon fazını ve 20 haftalık idame fazını içermektedir. Migren sıklığında bazal faz ölçümlerine göre 4. haftada saptanan azalma birincil etkinlik ölçütü olarak kabul edilmiştir. İkincil etkinlik ölçütleri ise cevap oranları, migren süre ve şiddetinde ortalama azalma olarak kabul edilmiştir. Baş ağrısının şiddeti, 10 puanlık vizüel analog skala (VAS) kullanılarak ölçülmüştür. Cevap oranları, aylık migren sıklığında ≥ %50 azalmanın görüldüğü hastaların yüzdesi olarak tanımlanmıştır. Bulgular: Yirmi sekiz haftanın sonunda migren sıklığında bazale göre saptanan azalma primer sonlanım ölçütüdür. Çalışma sonundaki ortalama migren sıklığı ilk grupta 1.27 ± 1 (bazal; ortalama ± SD: 3.6 ± 2) iken, ikinci grupta 1.2 ± 1.2’ dir (bazal; ortalama ± SD: 3.5 ± 2.3) (p

🔖

Cite This Article

KARAGÖZ, E. T., DEĞİRMENCİ, Y., KARAMAN, H. I. Ö. (2022). Divalproex sodium and topiramate for migraine prophylaxis. Journal of Clinical and Analytical Medicine, Cilt: 3 - Sayı: 3, 303–307. https://ajindex.com/articles/561364

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000;55(5):624-9
  2. Adelman JU, Adelman RD. Current options for the prevention and treatment of migraine. Clin Ther 2001;23(6):772-88
  3. Ducharme J. Canadian Association of Emergency Physicians guidelines for the acute management of migraine headache. J Emerg Med 1999;17(1):137-44
  4. Bigal ME, Krymchantowski AV, Rapoport AM. New developments in migraine prophylaxis. Expert Opin Pharmacother 2003;4(4):1-11
  5. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(6):754-62
  6. Silberstein SD. Migraine preventive treatment. Handb Clin Neurol. 2010;97:337-54
  7. Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009 May;27(2):429-43
  8. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52(3):281-6
  9. Ferran MD, Odink J, Bos KD, Matesty MCA, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990;40(10):1582-6
  10. Klapper J. Divalproex Sodium Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17(2):103-8
  11. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58 (11):1652-9
  12. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(Suppl 1):3-9
  13. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular traffic in the cat:a possible locus of action in the prevention of migraine. Neurology 2003; 60(Suppl 1):A238-9
  14. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J et al. Topiramate for migraine prevention. A randomized controlled trial. JAMA 2004; 291(8):965-73
  15. Martinez HR, Londono O, Cantu-Martinez L, Tarin LC, Castillo CD. Topiramate as adjunctive treatment in migraine prophylaxis. Headache 2003; 43(10):1080-4
  16. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia